Celcuity Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CELC | ORIC | RLAY | EXEL | IDYA | LEGN | |
|---|---|---|---|---|---|---|
| Market cap | 3.22B | 1.22B | 3.94B | 14.82B | 3.48B | 3.46B |
| P/E (TTM) | — | — | — | 18.9 | — | — |
| Forward P/E | -823.1 | -7.1 | -11.0 | 14.0 | -9.0 | 17.0 |
| Price/book | -252.3 | 3.2 | 4.4 | 8.1 | 2.9 | 2.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +42.53% | −13.80% | +185.17% | +55.72% | +34.89% | −43.32% |
| Today | −3.08% | −1.50% | +0.56% | −0.07% | −0.14% | −4.40% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CELC news ›Precision Trading with Celcuity Inc. (CELC) Risk Zones
Stock Traders Daily Key findings for Celcuity Inc. (NASDAQ: CELC) - Weak Near and Mid-Term Sentiment Could Pressure Neutral Long-Term Outlook - Elevated downside risk as no additional long-term support signals remain. - Signals: 67.94 ·…
Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026
Rapid oral presentation of additional sub-group analyses from the VIKTORIA-1 PIK3CA mutant-type cohort Poster presentation of a comparative analysis of data for the gedatolisib triplet from the PIK3CA wild-type cohort of VIKTORIA-1 and…
Celcuity Appoints David Gryska To Its Board Of Directors
The Manila Times Celcuity Appoints David Gryska To Its Board Of Directors Mr. Gryska brings decades of strategic and financial leadership experience to Celcuity’s Board MINNEAPOLIS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq:…
Celcuity appoints David W. Gryska as director and Audit & Compensation committee member
TradingView Celcuity appoints David W. Gryska as director and Audit & Compensation committee member Celcuity appointed David W. Gryska as a director, effective October 1, 2026, and named him to the Audit Committee and Compensation…
Why Celcuity Stock Was a Winner on Wednesday
On a generally forgettable Wednesday for the stock market, with many titles dropping in value, Celcuity (CELC +2.77%) stood out by posting a gain. Investors bought into the company, which is moving from the clinical to the commercial stage…
Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
Celcuity submitted a supplemental New Drug Application to the FDA in August for REVTORPYK to treat patients with HR+/HER2-, PIK3CA mutated, advanced breast cancer based on the results of Study 2 of the VIKTORIA-1 trial. If approved,…
CPKC announces C$1.8 billion debt offering
The shelf prospectus supplement, the corresponding base shelf prospectus and any amendment to the documents will be accessible through SEDAR+ within two business days
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
theglobeandmail.com4
-
manilatimes.net2
-
fool.com1
-
marketscreener.com1
-
news.stocktradersdaily.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 13 articles, not a forecast.